Sonoma Pharmaceuticals 관리

관리 기준 확인 3/4

Sonoma Pharmaceuticals CEO는 Amy Trombly, Sep2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 $ 726.54K, 44.7% 로 구성됩니다. 44.7% 급여 및 55.3% 보너스(회사 주식 및 옵션 포함). 는 $ 21.88K 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 21.88K. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 6.2 년입니다.

주요 정보

Amy Trombly

최고 경영자

US$726.5k

총 보상

CEO 급여 비율	44.7%
CEO 임기	5.2yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Recent updates

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 17

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Aug 27

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Jul 12

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

May 26

CEO 보상 분석

Amy Trombly 의 보수는 Sonoma Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$4m
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	US$727k	US$325k	-US$5m
Dec 31 2023	n/a	n/a	-US$5m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	US$560k	US$319k	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$5m
Mar 31 2022	US$643k	US$318k	-US$5m
Dec 31 2021	n/a	n/a	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	US$580k	US$300k	-US$5m
Dec 31 2020	n/a	n/a	-US$3m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	US$386k	US$153k	-US$4m

보상 대 시장: Amy 의 총 보상 ($USD 726.54K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 649.07K ).

보상과 수익: 회사가 수익성이 없는 동안 Amy 의 보상이 증가했습니다.

CEO

Amy Trombly (56 yo)

5.2yrs

테뉴어

US$726,543

보상

Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 27, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Amy Trombly	CEO, President & Director	5.2yrs	US$726.54k	0.57% $ 21.9k
Jerome Dvonch	Chief Financial Officer	1.6yrs	US$307.46k	0.32% $ 12.1k
Bruce Thornton	Executive VP	4.6yrs	US$658.67k	0.58% $ 22.0k
John Poggetto	Controller	1.3yrs	US$479.59k	0.056% $ 2.1k

3.1yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: SNOA 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Amy Trombly	CEO, President & Director	2.3yrs	US$726.54k	0.57% $ 21.9k
John McLaughlin	Lead Independent Director	11.7yrs	US$65.00k	0.020% $ 772.5
Philippe Weigerstorfer	Independent Director	6.2yrs	US$47.50k	데이터 없음
Jay Birnbaum	Independent Director	17.6yrs	US$55.00k	0.021% $ 817.9
Hye Chung	Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

70.5yo

평균 연령

경험이 풍부한 이사회: SNOA 의 이사회는 경험(평균 재직 기간 6.2 년)으로 간주됩니다.

Sonoma Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Recent updates

Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

First quarter 2025 earnings: EPS and revenues miss analyst expectations

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New minor risk - Share price stability

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

New major risk - Share price stability

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

New 90-day high: US$9.64

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals reports FQ2 results

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals, Inc. Plans to Relocate Remaining Manufacturing to Mexico

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

CEO 보상 분석

CEO

테뉴어

보상